Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Other Nov 23 | 2021Medtronic CY Q3 '21 (FY Q2 '22) Earnings Update; HAGAR’s GWave Receives Breakthrough Device Designation; Oramed Randomizes 75% of Patients in Oral Insulin Trial; Beyond Type 1 Launches Web Platform in ArabicPurchase Blast
$599
Posted in: Dual/triple agonist, Other Nov 22 | 2021Intarcia Files Notice of Opportunity for a Hearing; Provention Bio Advances popPK Model for Teplizumab; Zealand Announces Dapiglutide Topline ResultsPurchase Blast
$599
Posted in: Other Nov 18 | 2021Teladoc Hosts 2021 Investor Day; Better Therapeutics Pivotal BT-001 Trial for T2DM Completes Enrollment; Dario Announces New Employer ContractsPurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Nov 16 | 2021Viatris/Biocon Launch Interchangeable Semglee in US; Lexicon Presents SOLOIST/SCORED Renal Subcuts at AHA; CRISPR/ViaCyte to Initiate Ph1 Trial in T1DM; Innovation Zed Announces InsulCheck DOSE 2022 Launch; Nemaura and Dario Q3 '21 Earnings UpdatesPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Nov 12 | 2021Novo’s High-Dose Ozempic Receives Positive CHMP Opinion; Movano Q3 '21 Earnings UpdatePurchase Blast
$599
Posted in: Other, SGLT2i Nov 12 | 2021AZ Q3 ’21 Earnings Update; J&J to Split Consumer and Pharma/Med Device BusinessPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Nov 11 | 2021BI/Lilly’s Jardiance Receives FDA Priority Review; Novo’s Wegovy Receives Positive CHMP Opinion; Merck/Bayer Initiate New Ph3 Verquvo Study; Dario Enters Three New Commercial Agreements; Gmax Administers First in Human Dose of GMA106 in Ph1 Obesity Study; Metacrine and Zealand Q3 ’21 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Glucagon, Insulin Delivery, Other Nov 10 | 2021MannKind and Xeris Biopharma Q3 ’21 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i Nov 09 | 2021Bayer and Senseonics Q3 '21 Earnings Updates; Abbott and ADA Launch Community Initiative; Provention Bio Launches #Type1TestedPledge Campaign; Beyond Type 1 Receives $750,000 GrantPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, Other Nov 08 | 2021November 8-11 CHMP Agenda; Kerendia+SGLT2i Reduce Risk of Composite CV Outcome; Viatris Q3 ’21 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Nov 05 | 2021GSK’s Daprodustat Ph3 Data Positive But Not Entirely Clean; BI/Lilly’s Jardiance Demonstrates Consistent Cardio-Renal Benefits in HF; Novo Announces Positive Ph3b STEP 5 Trial Results; CytoDyn Reports Positive Preliminary Data from Ph2 Leronlimab Trial; Roche and Sanofi Mallya Collaboration; Intuity Medical’s Automatic BGM Available in US; Zealand and DEKA Collaboration for Continuous Infusion PumpPurchase Blast
$599
Posted in: Basal Insulin, Insulin Delivery, Other Nov 04 | 2021Viatris’s Semglee Gains Preferred Status on Prime Therapeutics’s National Formularies; Zealand’s First Patient Dosed with ZP8396 in Ph1 Trial for Obesity; Insulet, Lannett, Ionis, Provention Bio, BD, and Regeneron Q3 ‘21 Earnings UpdatesPurchase Blast
$599
Posted in: Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Nov 03 | 2021Lexicon, Tandem, Amarin, Intercept, and Amgen Q3 '21 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other Nov 03 | 2021Novo Nordisk Q3 '21 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Other, SGLT2i Nov 02 | 2021Ionis Initiates New Ph3 Study in Hypertriglyceridemia; Real-World Evidence Study of PDT BT-001 for T2DM; Metacrine Announces MET409 Topline Results; Esperion and Pfizer Q3 ’21 Earnings UpdatesPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring, Other Nov 01 | 2021Zealand Announces Presentation of Preclinical and Clinical Data on ZP8396 and BI 456906; BING Innovations Launches DigiVibe; Dario Signs Remote Patient Monitoring Services Contracts; National Diabetes Awareness Month ActivitiesPurchase Blast